2007PanCAN膵臓がんサミット参加レポート（大内田研宙氏）－２

作者 Administrator

2007/11/29 Thursday 14:32:37 JST

PUBLICATIONS 1. Kenoki Ohuchida, K Mizumoto, Y Miyasaka, Y Jun, C Lin, H Yamaguchi, H Toma, S Takahata, N Sato, E Nagai, K Yamaguchi, M Tsuneyoshi and M Tanaka　 Overexpression of S100A2 in pancreatic cancer is correlated with tumor progression and poor prognosis Journal of Pathology in press 2007 2. Kenoki Ohuchida, Kazuhiro Mizumoto, Seiji Ohhashi, Hiroshi Yamaguchi, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. Twist, a novel oncogene, is up-regulated in pancreatic cancer; Clinical implication of Twist expression in pancreatic juice. Int J Cancer, 120:1634-40, 2007 3. Kenoki Ohuchida, K Mizumoto, J Yu, H Yamaguchi, H Konomi, E Nagai, Koji Yamaguchi, M Tsuneyoshi, and M Tanaka. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: Clinical value of expression analysis in 93 pancreatic juice samples. Cancer Epidemiology, Biomarkers & Prevention, 16:649-54 2007 4. Y Miyasaka, E Nagai, H Yamaguchi, K Fujii, T Inoue, Kenoki Ohuchida, T Yamada, K Mizumoto, M Tanaka, M Tsuneyoshi. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas.Clin Cancer Res. 13:4371-7. 2007 5. Hiroshi Yamaguchi, Inoue T, Eguchi T, Miyasaka Y, Kenoki Ohuchida, Mizumoto K, Yamada T, Yamaguchi K, Tanaka M, Tsuneyoshi M Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Modern Pathology, 20;552-61 2007 6. Daisuke Yamada, Kenoki Ohuchida, K Mizumoto, S Ohhashi, Jun Yu, T Egami, H Fujita, E Nagai and M Tanaka. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Aanticancer Research;27:793-800, 2007 7. Kenoki Ohuchida, Kazuhiro Mizumoto, D Yamada, Kei Fujii, Nami Ishikawa, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi and Masao Tanaka. Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. Int J Cancer;118(2):405-11, 2006. 8. Kenoki Ohuchida, K Mizumoto, D Yamada, H Yamaguchi, H Konomi, E Nagai, K Yamaguchi, M Tsune, and M Tanaka. Quantitative analysis of human telomerase reverse transcriptase in pancreatic cancer. Clin Cancer Res;12 2066-9, 2006 9. Kenoki Ohuchida, Kazuhiro Mizumoto, Hayato Fujita, H Yamaguchi, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi7, and Masao Tanaka7. Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasm: clinical implications of mRNA levels in pancreatic juice. Journal of Pathology, 210: 42-48, 2006 10. Kenoki Ohuchida, Kazuhiro Mizumoto, T Egami, H Yamaguchi, H Konomi, E Nagai, Koji Yamaguchi, M Tsuneyoshi, and Masao Tanaka. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res; 12(18): 5411-6, 2006 11. Kenoki Ohuchida, Kazuhiro Mizumoto, Seiji Ohhashi, Hiroshi Yamaguchi, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, and Masao Tanaka. S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res; 12(18): 5417-22, 2006 12. Jun Yu, Kenoki Ohuchida, K Mizumoto, N Ishikawa, Y Ogura, D Yamada, Takuya Egami, Hayato Fujita, Seiji Ohashi, Eishi Nagai, Masao Tanaka. Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroentero. 12(24) 3878-82, 2006 13. Ogura Y, Mizumoto K, Tanaka M, Kenoki Ohuchida, Murakami M, Yamada D, Ishikawa N, Nagai E. Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model. Surgery;140(1):66-71, 2006 14. N Ishikawa, T Miya, K Mizumoto, Kenoki Ohuchida, Eishi Nagai, Koji Yamaguchi, Masahiro Amano, Shigeori Takenaka, and Masao Tanaka. Rapid and Sensitive Assay of K-ras Mutations in Pancreatic Cancer by Electrochemical Detection with Ferrocenyl-naphthalene-diimide. Cancer genomics & Proteomics; 3: 47-54, 2006 15. Kenoki Ohuchida, Kazuhiro Mizumoto, Yasuhiro Ogura, Nami Ishikawa, Eishi Nagai, Koji Yamaguchi, and Masao Tanaka. Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer. Clin Cancer Res;11(6):2285-92, 2005. 16. Kenoki Ohuchida, Kazuhiro Mizumoto, Nami Ishikawa, Kei Fujii, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi7, and Masao Tanaka7. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res;11(21):7785-93, 2005 17. Murakami M, Nagai E, Mizumoto K, Saimura M, Ohuchida Kenoki, Inadome N, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer.; 117:160-5, 2005 18. Kawin Leelawat, Kenoki Ohuchida, K Mizumoto, C Mahidol, M Tanaka. All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. CANCER letters; 224: 303-310, 2005 19. Kenoki Ohuchida, Kazuhiro Mizumoto, Mitsuhiko Murakami, Li-Wu Qian, Norihiro Sato, Eishi Nagai, Kunio Matsumoto, Toshikazu Nakamura, and Masao Tanaka. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Research; 64: 3215-3222, 2004 20. Kenoki Ohuchida, K Mizumoto, N Ishikawa, N Sato, E Nagai, K Yamaguchi, H Takaishi, T Ide, and M Tanaka. A highly-sensitive and quantitative telomerase activity assay with pancreatic juice is useful for diagnosis of pancreatic cancer without problems due to PCR inhibitors. CANCER;101:2309-17, 2004 21. Hirokazu Noshiro, Shuji Shimizu, Eishi Nagai, Kenoki Ohuchida, and Masao Tanaka. Laparoscopy-assisted distal gastrectomy for early gastric cancer. Is it beneficial for patients of heavier weight? Annals of Surgery; 238: 680-685, 2003 22. L Qian, K Mizumoto, N Maehara, Kenoki Ohuchida, N Inadome, M Saimura, E Nagai, K Matsumoto, T Nakamura, M Tanaka. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimutate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production CANCER Letters 190 105-112, 2003

最終更新日 ( 2007/12/23 Sunday 05:53:33 JST )

 

< 前へ		次へ >

Display News

Research - News 膵がん治療の最前線を探る（その２） Editor - 2008/11/11 Tuesday 16:49:41 JST ■膵がん研究の最前線から見えてきた膵がん発症のメカニズム 膵 がん診療で世界をリードするJohns Hopkins病院。一方、教育・研究機関であるJohns Hopkins大学は膵がんの研究で世界を牽引している。同大学内にある全米家族性膵がん登録制度のオフィスを訪問し、膵がんの発症に関わる遺伝子研究の 最前線を垣間見た。 【寄稿】パンキャンジャパン・アメリカ訪問記－その2　 詳しくはこちら（がんナビ） Research - News 膵がん診療の最前線を探る（その１） Editor - 2008/11/09 Sunday 20:35:12 JST ■膵がん診療の最前線を探る 膵臓がん（膵がん）の診療・研究で世界をリードするメリーランド州バルチモア市に位置するJohns Hopkins病院。同病院は、US. News & World Report誌による全米病院ランキングで第1位であり、膵がん治療の患者数も治療成績においても全米第１位だ。膵がん診療の最前線を報告したい。 【寄稿】パンキャンジャパン・アメリカ訪問記－その１　 詳しくはこちら（がんナビ） Research - News 膵臓がん研究の最前線：　遺伝子と家族性膵がんについて Administrator - 2008/07/29 Tuesday 01:49:08 JST 膵臓がん研究の最前線：　遺伝子と家族性膵がんについて ジョンホプキンス大学Sol Goldman Pancreatic Cancer Research Center所長、PanCANの科学諮問委員会メンバーでもある　Ralph Hruban氏に膵臓がん研究の最前線、特に膵がんに関連する遺伝子異常と早期発見・治癒が期待される家族性膵がんの研究についてお話を伺いました。 　　　　　　　＊　　　　　　　　　　＊　　　　　　　　　　＊　　　　　　　　　　　　　　　　　　　　　 Research - News 膵臓がんリサーチマップ（PCRM）－　NCIとPanCANのコラボレーション Administrator - 2008/03/19 Wednesday 11:32:35 JST 膵臓がんアクションネットワーク（PanCAN）は米国国立がん研究所（NCI）と協力し、膵臓がんに関する研究者、研究助成金、臨床試験、研究プロジェクトを追跡、把握する「膵臓がんリサーチマップ（PCRM）」を2004年11月8日、膵臓がん注意月間（Pancreatic Cancer Awareness Month）の開催と平行してWeb上に立ち上げた。目的は、膵臓がん研究のスピードを上げること、研究分野で研究者のニーズと助成金などの支援の間にギャップがあるかチェックすること、また、がん研究情報を収集・活用し研究促進に貢献するひとつのモデルになることである。 Research - News 2007膵臓がんサミット・ウェブキャスト Administrator - 2007/12/31 Monday 12:08:01 JST 2007年8月2日から5日までカリフォルニア州ラホヤ市においてPanCANが主催した「膵臓がんサミット」のセッションを収録した動画です。膵癌と生物学の著名な研究者が参加して開かれた当会議では、膵癌に関する未発表の研究成果も含めたレビューがプレゼンされ、今後5年間の「機会と挑戦」についての対話的な議論がなされました。